Gene Symbol |
BRCC3
|
Entrez Gene |
79184
|
Alt Symbol |
BRCC36, C6.1A, CXorf53
|
Species |
Human
|
Gene Type |
protein-coding
|
Description |
BRCA1/BRCA2-containing complex, subunit 3
|
Other Description |
BRCA1-A complex subunit BRCC36|BRCA1/BRCA2-containing complex subunit 36|BRISC complex subunit BRCC36|lys-63-specific deubiquitinase BRCC36
|
Swissprots |
Q16107 A9Z1Y5 Q9BTZ6 B1B062 B4DQN7 A6QRF8 P46736 Q53YX5 A8MWH0 A6QRF9 A8MUX5 A9Z1Y0
|
Accessions |
EAW72632 EAW72633 EAW72634 EAW72635 EAW72636 EAW72637 P46736 AK298886 BAG60999 AK299194 BAG61237 AK310286 AK313544 BAG36320 AM392829 CAL37707 AY438030 AAR30498 BC002999 AAH02999 BC006540 AAH06540 BP304352 BU902387 S68015 AAB29005 X64643 CAA45917 XM_005274751 XP_005274808 NM_001018055 NP_001018065 NM_001242640 NP_001229569 NM_024332 NP_077308
|
Function |
Metalloprotease that specifically cleaves 'Lys-63'- linked polyubiquitin chains. Does not have activity toward 'Lys- 48'-linked polyubiquitin chains. Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). In the BRCA1-A complex, it specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double- strand breaks (DSBs). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates. Mediates the specific 'Lys-63'- specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex. {ECO:0000269|PubMed:14636569, ECO:0000269|PubMed:16707425, ECO:0000269|PubMed:17525341, ECO:0000269|PubMed:1920
|
Subcellular Location |
Nucleus {ECO:0000269|PubMed:18077395, ECO:0000269|PubMed:19202061, ECO:0000269|PubMed:19261748, ECO:0000269|PubMed:19261749}. Note=Localizes at sites of DNA damage at double-strand breaks (DSBs).
|
Tissue Specificity |
Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Aberrantly expressed in the vast majority of breast tumors. {ECO:0000269|PubMed:16707425}.
|